Siirry sisältöön
Press Release_Lokon Pharma selects Biovian as a CDMO

Lokon Pharma AB signs an agreement with Biovian

Lokon Pharma AB, a company developing next-generation cancer therapeutics, has selected Biovian Oy as a CDMO partner for GMP manufacturing of LOAd703 for a pivotal randomized study. The uniquely engineered LOAd703 oncolytic virus is currently …
Biovian Blog

4 Areas where a CDMO can help your Viral Vector project.

The therapeutic possibilities of cell and gene therapy are very appealing. The possibility to use a Viral Vector to carry the therapeutic gene into the target cells or to initiate cell transduction holds the potential …